Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Jason Gilbert, Diana Abbott, Elizabeth Molina Kuna, Marcelo Perraillon, Anand Patel, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2025-2853

Published: 2025

Journal Articles

Analysis of CD8 cytotoxic t-cells in patients with myelodysplastic syndrome (MDS) and T-cell large granulocyte lymphocytic leukemia (T-LGLL) reveal a distinct phenotype compared to those with t-lgll

Makenna May, Cassandra Duarte, Rosana Moreira Pereira, Jamie Borg, Kellen Gil, Monica Ransom, William Showers, Jingjing Zhang, Daniel Pollyea, Nathaly Limon De La Rosa, Bradley Haverkos, Austin Gillen, Carlo Marchetti, Maria Amaya

Blood (2025) 146 (Supplement 1): 5610.

https://doi.org/10.1182/blood-2025-5610

Published: 2025

Journal Articles

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Blood (2025) 146 (Supplement 1): 220.

https://doi.org/10.1182/blood-2025-220

Published: 2025

Journal Articles

Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies

Meredith Beaton, Michelle Springer, Cailin Collins, Mathew Angelos, Andrew Kent, Maria Amaya, Jonathan Gutman, Marc Schwartz, Danica Wiredja, Michael Clay, Alisa Gaskell, Nicholas Willard, Daniel Pollyea, Christine McMahon

Blood (2025) 146 (Supplement 1): 1084.

https://doi.org/10.1182/blood-2025-1084

Published: 2025

Journal Articles

Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations

Allyson Freedy, Danica Wiredja, Jingjing Zhang, Christine McMahon, Mathew Angelos, Maria Amaya, Jonathan Gutman, Marc Schwartz, Daniel Pollyea, Andrew Kent

Blood (2025) 146 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2025-7018

Published: 2025

Journal Articles

The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

Michael Jones, Cailin Collins, Danica Wiredja, Jingjing Zhang, Christine McMahon, Mathew Angelos, Maria Amaya, Jonathan Gutman, Marc Schwartz, Daniel Pollyea, Andrew Kent

Blood (2025) 146 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2025-3478

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)

Christine McMahon, Mathew Angelos, Andrew Kent, Maria Amaya, Marc Schwartz, Jonathan Gutman, Michael Clay, Danica Wiredja, Nicholas Willard, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 5287.

https://doi.org/10.1182/blood-2025-5287

Published: 2025

Journal Articles

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Marc Schwartz, Navin Pinto, Michael Verneris, Daniel Pollyea, Christine McMahon, Jonathan Gutman, Angela Ohm, Maria Amaya, Andrew Kent, Mathew Angelos, Cheri Adams, Bonnie Yates, Katie Anttila, Jessica Dell-Martin, Kimberly Jordan, Terry Fry

Blood (2025) 146 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2025-4165

Published: 2025

Journal Articles

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 292.

https://doi.org/10.1182/blood-2025-292

Published: 2025

Journal Articles

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Cassandra Duarte, Diana Abbott, Grace N Bosma, Christine M. McMahon, Jonathan A Gutman, Marc Schwartz, Daniel Pollyea, Maria L Amaya

Blood (2023) 142 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2023-174996

Published: 2023

Journal Articles

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Hunter Tolison, Cassandra Duarte, Glen Peterson, Grace N Bosma, Diana Abbott, Gemlyn George, Daniel Pollyea, Craig T. Jordan, Maria L Amaya

Blood (2023) 142 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2023-179669

Published: 2023

Journal Articles

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 292.

https://doi.org/10.1182/blood-2023-182967

Published: 2023

Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 327.

https://doi.org/10.1182/blood.V126.23.327.327

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

Characterization and Targeting of Myelodysplastic Syndrome Stem Cells

Brett M Stevens, PhD, Daniel Pollyea, MD MS, Nabilah Khan, PhD, Craig T Jordan, PhD

Blood (2015) 126 (23): 4104.

https://doi.org/10.1182/blood.V126.23.4104.4104

Published: 2015

Journal Articles

Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia

Simone Riedel, PhD, Jessica Haladyna, BA, Brett Stevens, Craig T Jordan, PhD, Daniel Pollyea, MD MS, Scott A. Armstrong, MD PhD, Qi Wei, PhD, Patricia Ernst, PhD, Tobias Neff, MD, Kathrin M Bernt, MD

Blood (2015) 126 (23): 2428.

https://doi.org/10.1182/blood.V126.23.2428.2428

Published: 2015

Journal Articles

Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function

Shanshan Pei, PhD, Mohammad Minhajuddin, PhD, Brett M Stevens, PhD, Biniam Adane, Nabilah Khan, PhD, Angelo D'alessandro, PhD, Travis Nemkov, Kirk C Hansen, PhD, Daniel Pollyea, MD MS, Craig T Jordan, PhD

Blood (2015) 126 (23): 842.

https://doi.org/10.1182/blood.V126.23.842.842

Published: 2015

Journal Articles

IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience

Zohra Nooruddin, MD, William Robinson, MD PhD, Daniel Pollyea, MD MS, Jonathan A Gutman, MD, Clayton Smith, MD FRCPC, Zenggang Pan, MD, Craig T Jordan, PhD, Rachel Rabinovitch, MD, Jeffrey Schowinsky, Xian Lu, PhD, Douglas Ney, MD, Manali Kamdar, MD

Blood (2015) 126 (23): 1443.

https://doi.org/10.1182/blood.V126.23.1443.1443

Published: 2015

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Analysis of CD8 cytotoxic t-cells in patients with myelodysplastic syndrome (MDS) and T-cell large granulocyte lymphocytic leukemia (T-LGLL) reveal a distinct phenotype compared to those with t-lgll

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies

Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations

The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

The Genomic and Transcriptomic Landscape of Myeloid Sarcoma and Associated Acute Myeloid Leukemia

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Characterization and Targeting of Myelodysplastic Syndrome Stem Cells

Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia

Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function

IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only